Practices that build a clear intake process for GLP-1 eligibility screening now will handle the volume
Not replicated in humans at this point, though there are people online who have stopped and started with worse results than expected after restarting, so if this turns out to be a real and substantial effect in humans , it is a very strong argument against cycling GLPs, especially if there is any underlying obesity issues, as messing up the effectiveness of the drugs that work long term does not sound like a good idea to get marginally lower body fat
Because the medication intentionally slows gastric emptying, some patients may experience nausea, fullness, or bloating, symptoms similar to gastroparesis
Conversely, people with long-standing obesity, multiple weight-loss attempts, or genetic predispositions to weight gain may find ongoing or cyclical treatment more realistic than stopping abruptly